These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28645443)

  • 21. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis.
    Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
    Renda G; Ricci F; Giugliano RP; De Caterina R
    J Am Coll Cardiol; 2017 Mar; 69(11):1363-1371. PubMed ID: 28302287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of non-vitamin K antagonist oral anticoagulants versus warfarin in heart failure patients with atrial fibrillation.
    Chen F; Zhou Y; Wan Q; Yu P; Ma J; Hu J
    Heart Fail Rev; 2021 Nov; 26(6):1391-1397. PubMed ID: 32249407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
    Emren SV; Zoghi M; Berilgen R; Özdemir İH; Çelik O; Çetin N; Enhoş A; Köseoğlu C; Akyüz A; Doğan V; Levent F; Dereli Y; Doğan T; Başaran Ö; Karaca I; Karaca Ö; Otlu YÖ; Özmen Ç; Coşar S; Sümerkan M; Gürsul E; İnci S; Onrat E; Ergene O
    Bosn J Basic Med Sci; 2018 May; 18(2):185-190. PubMed ID: 28968197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis.
    Sen P; Kundu A; Sardar P; Chatterjee S; Nairooz R; Amin H; Aronow WS
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):33-41. PubMed ID: 26138204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies.
    Zhang C; Gu ZC; Ding Z; Shen L; Pan MM; Zheng YL; Lin HW; Pu J
    Thromb Res; 2019 Feb; 174():16-23. PubMed ID: 30551039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
    Wang KL; Chiu CC; Giugliano RP; Tan DS; Lin CY; Lai EY; Goto S; Chiang CE
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):857-864. PubMed ID: 29239808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
    Carnicelli AP; Hong H; Giugliano RP; Connolly SJ; Eikelboom J; Patel MR; Wallentin L; Morrow DA; Wojdyla D; Hua K; Hohnloser SH; Oldgren J; Ruff CT; Piccini JP; Lopes RD; Alexander JH; Granger CB;
    Am Heart J; 2021 Mar; 233():48-58. PubMed ID: 33296688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracranial arterial and venous thromboembolism in patients with atrial fibrillation: A meta-analysis of randomized controlled trials.
    Wang KL; Büller HR; Goto S; Lin CY; Lai EY; Chiu CC; Chiang CE; Giugliano RP
    Heart Rhythm; 2017 Apr; 14(4):599-605. PubMed ID: 28062249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis.
    Liao XZ; Fu YH; Ma JY; Zhu WG; Yuan P
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):391-399. PubMed ID: 32206988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients.
    Capodanno D; Capranzano P; Giacchi G; Calvi V; Tamburino C
    Int J Cardiol; 2013 Aug; 167(4):1237-41. PubMed ID: 22494863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials.
    Carmo J; Ferreira J; Costa F; Carmo P; Cavaco D; Carvalho S; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Oct; 244():196-201. PubMed ID: 28679480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials.
    Li G; Holbrook A; Jin Y; Zhang Y; Levine MA; Mbuagbaw L; Witt DM; Crowther M; Connolly S; Chai-Adisaksopha C; Wan Z; Cheng J; Thabane L
    Eur J Epidemiol; 2016 Jun; 31(6):541-61. PubMed ID: 27370013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis.
    Wang X; Fang L; Liu B; Zheng Y; Zeng J
    Heart Fail Rev; 2020 Nov; 25(6):973-983. PubMed ID: 31713086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach.
    Verdecchia P; Angeli F; Bartolini C; De Filippo V; Aita A; Di Giacomo L; Poltronieri C; Lip GY; Reboldi G
    Expert Opin Drug Saf; 2015 Jan; 14(1):7-20. PubMed ID: 25311731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
    Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
    Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
    [No Abstract]   [Full Text] [Related]  

  • 37. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yan BP; Yu CM
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):23-35. PubMed ID: 23224686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of the efficacy and safety of non-vitamin K antagonist oral anticoagulants with warfarin in Latin American patients with atrial fibrillation.
    Su Z; Zhang H; He W; Ma J; Zeng J; Jiang X
    Medicine (Baltimore); 2020 May; 99(18):e19542. PubMed ID: 32358343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.